News - North America, Halozyme Therapeutics

Filter

Popular Filters

Baxter files amended BLA to FDA for HyQvia for primary immunodeficiency

Baxter files amended BLA to FDA for HyQvia for primary immunodeficiency

02-12-2013

USA-based Baxter International has completed submission of an amended biologics license application to…

Baxter InternationalHalozyme TherapeuticsHyQviaImmunologicalsNorth AmericaPharmaceuticalRegulationUSA

Halozyme plunges as FDA call for more data on HyQ BLA

17-04-2012

USA-based Halozyme Therapeutics saw its shares plummet 24% to $8.56 by close of trading yesterday, after…

Baxter InternationalBiotechnologyHalozyme TherapeuticsHyQImmunologicalsNorth AmericaRegulation

Back to top